Global Small Molecule Injectable Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Small Molecule Antibiotics, Analgesics, Chemotherapy, Antivirals, Anticoagulant, Skeletal Muscle Relaxants, Anticonvulsants, and Others), By Indication (Pain Management, Oncology, Infectious Diseases, Cardiovascular Diseases, CNS Diseases, and Others), By Mode of Delivery (IV Set, Intravenous Injection, Infusion Pump, Intramuscular Injection and Subcutaneous Injection), and by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 - 2030

Industry: Healthcare

RELEASE DATE Oct 2022
REPORT ID SI1217
PAGES 240
REPORT FORMAT PathSoft

Global Small Molecule Injectable Drugs Market Insights Forecasts to 2030

  • The global small molecule injectable drugs market was valued at USD 188.9 billion in 2021.
  • The market is growing at a CAGR of 8% from 2021 to 2030
  • The global small molecule injectable drugs market is expected to reach USD 837.8 billion by 2030
  •  Europe is expected to grow the fastest during the forecast period

Small Molecule Injectable Drugs Market

Get more details on this report -

Request Free Sample PDF

The global Small Molecule Injectable Drugs Market is expected to reach USD 837.8 billion by 2030, at a CAGR of 8% during the forecast period 2021 to 2030. The Small Molecule Injectable Drugs Market has been growing owing to the increasing applications of Injectable drugs.

 

Market Overview:

Small molecule injectable drugs play an essential role in the treatment of all different kinds of diseases, including cancer disorders, infectious diseases, blood diseases, and cardiovascular diseases. This is despite the expansion of biologic pharmaceuticals. In many cases, the treatment of patients requires the use of injectable medications that are composed of small molecules. According to the estimates provided by the Congressional Budget Office, sales of small-molecule pharmaceuticals were 84% of the total income generated by the pharmaceutical sector. In addition, short molecule APIs were utilized in developing five of the top ten pharmaceuticals in terms of income and nine of the top ten drugs in terms of frequency of prescription. An intravenous medicine infusion can have a quick therapeutic impact since this method delivers the medication directly into circulation. Such quick administration is required to treat patients with small molecule medications effectively. This type of distribution is typically required in hospitals, either in the event of an emergency or if unanticipated difficulties arise. In certain conditions, patients cannot take their prescriptions by mouth; in these instances, the most efficient method of pharmaceutical delivery is by injection or infusion. In some cases, the active pharmaceutical ingredients (APIs) may be broken down in the digestive system, necessitating distribution via the parenteral route. In addition, injectable goods are made according to very stringent requirements of both quality and sterility.

 

Report Coverage

This research report categorizes the market for global Small Molecule Injectable Drugs based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global Small Molecule Injectable Drugs market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each global Small Molecule Injectable Drugs market sub-segments.

 

Global Small Molecule Injectable Drugs Market Report Coverage

Report CoverageDetails
Base Year:2021
Market Size in 2021:USD 188.9 billion
Forecast Period:2021-2030
Forecast Period CAGR 2021-2030 : 8%
2030 Value Projection:USD 837.8 billion
Historical Data for:2017-2020
No. of Pages:240
Tables, Charts & Figures:185
Segments covered:By Drug Class, By Indication, By Mode of Delivery, by Region, COVID-19 Impact Analysis
Companies covered::Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals plc.  
Pitfalls & Challenges:COVID-19 has the potential to impact the global market

Get more details on this report -

Request Free Sample PDF
 

Segmentation Analysis

  • In 2021, the small molecule antibiotics segment dominated the market with the largest market share of 20% and market revenue of 37.78 billion.

Based on the drug class type, the small molecule injectable drugs market is categorized into small molecule antibiotics, analgesics, chemotherapy, antivirals, anticoagulant, skeletal muscle relaxants, anticonvulsants, and others. In 2021, the small molecule antibiotics segment dominated the market with the largest market share of 20% and market revenue of 37.78 billion. Antibiotic medications are widely used in the treatment of bacterial infections as well as the prevention of these infections. Small molecule antibiotics are the most important antibacterial agent for fighting bacterial infections. It is considered the most common type of antibacterial agent. They could eliminate germs entirely or only slow down their reproduction.

 

  • In 2021, the infectious disease segment dominated the market with the largest market share of 21% and market revenue of 39.6 billion.

Based on the indication type, the small molecule injectable drugs market is categorized as pain management, oncology, infectious diseases, cardiovascular diseases, CNS diseases, and others. In 2021, the infectious disease segment dominated the market with the largest market share of 21% and market revenue of 39.6 billion. Infectious diseases are afflicting a significant number of people worldwide, and it is anticipated that an increase in the prevalence of infectious diseases would lead to an increase in the need for small-molecule injectable medications. This is the primary factor behind the expansion of the market.

 

  • In 2021, the intravenous injection segment accounted for the largest share of the market, with 30% and a market revenue of 56.67 billion.

Based on the mode of delivery, the small molecule injectable drugs market is categorized into IV set, intravenous injection, infusion pump, intramuscular injection, and subcutaneous injection. In 2021, the intravenous injection segment dominated the market with the largest market share of 30% and market revenue of 56.67 billion. Drugs and fluids are injected directly into the circulatory system via the intravenous route, and swiftly disseminated throughout the body. This makes the intravenous route the quickest means to administer these substances throughout the body. This is the primary factor behind the expansion of the market.

 

Regional Segment Analysis of the Small Molecule Injectable Drugs Market

 

Small Molecule Injectable Drugs Market

Get more details on this report -

Request Free Sample PDF
  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America)
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

Among all regions, North America emerged as the largest market for the global small molecule injectable drugs market, with a market share of around 37% and 69.89 billion of the market revenue in 2021.

  • In 2021, North America emerged as the largest market for the global small molecule injectable drugs market, with a market share of around 37% and 69.89 billion of the market revenue. The market for small molecule injectable drugs in the North American region has been expanding owing to the increasing rising R&D activities by several small and medium enterprises to develop medical healthcare facilities in the healthcare sector. Due to the growing number of product approvals by regulatory bodies, the market for small molecule injectable pharmaceuticals in North America is anticipated to dominate throughout the forecast period.

 

  • The Europe market is expected to grow at the fastest CAGR between 2021 and 2030, owing to the increasing demand for several applications such as catheters & cannulas, drug delivery systems, bulk medical tubing, and other special applications (smoke evacuation tubing and peristaltic pump tubing). Furthermore, the rise in medical accessibility and the growing need for minimally invasive medical procedures fuels the market’s growth in the region. The multiplying middle-class population in the UK and Germany increases the demand for minimally invasive techniques. There is an advancement in the efficient medical devices in the region coupled with the increasing interest of people in taking care of elderly people at home with easy & simple products.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Small Molecule Injectable Drugs Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Market Players:

  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AstraZeneca Plc
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Cipla Limited.
  • Mylan N.V.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche AG (Genentech, Inc.)
  • Amgen, Inc., Gilead Sciences, Inc.
  • Hikma Pharmaceuticals plc.  

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities
  • Consulting And Research Firm
  • Venture capitalists
  • Third-party knowledge providers
  • Value-Added Resellers (VARs)

Recent Development

  • In January 2021, The FDA of the United States approved the drug Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for treating human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed on a stable antiretroviral. This was announced by ViiV Healthcare, a pharmaceutical company that specializes in the development of treatments for HIV infection.
  • In October 2021, The CUBICIN (daptomycin for injection) 500mg designed for intravenous administration was voluntarily recalled by Merck & Co., according to a statement from the US Food and Drug Administration (FDA). The recall is being carried out at the user level, including hospitals and other organisations in charge of dispensing the medication, as it is anticipated that treatment with CUBICIN will begin in a hospital or another monitored healthcare environment. As a result of this recall, some 22,000 vials were taken off the shelves.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Small molecule injectable drug delivery market based on the below-mentioned segments:

Global Small Molecule Injectable Drugs Market, By Drug Class

  • Small Molecule Antibiotics
  • Analgesics
  • Chemotherapy
  • Antivirals
  • Anticoagulant
  • Skeletal Muscle Relaxants
  • Anticonvulsants
  • Others

Global Small Molecule Injectable Drugs Market, By Indication

  • Pain Management
  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Diseases
  • Others

Global Small Molecule Injectable Drugs Market, By Mode of Delivery

  • IV Set
  • Intravenous Injection
  • Infusion Pump
  • Intramuscular Injection
  • Subcutaneous Injection

Global Small Molecule Injectable Drugs Market, Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions (FAQ)

  • What is the market size of the Small Molecule Injectable Drugs market?
    As per Spherical Insights, the size of the Small Molecule Injectable Drugs market was valued at USD 188.9 billion in 2021 to USD 837.8 billion by 2030.
  • What is the market growth rate of the Small Molecule Injectable Drugs market?
    The Small Molecule Injectable Drugs market is growing at a CAGR of 8% during the forecast period 2021-2030.
  • Which country dominates the Small Molecule Injectable Drugs market?
    North America emerged as the largest market for Small Molecule Injectable Drugs.
  • Who are the key players in the Small Molecule Injectable Drugs market?
    Key players in the Small Molecule Injectable Drugs market are Novartis AG: Pfizer Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals plc.
  • Which is the leading drug class for Small Molecule Injectable Drugs Market?
    The small molecule antibiotics segment is the leading drug type for the Small Molecule Injectable Drugs market.

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies